Gilead Sciences (NQ:GILD)

144.74 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

78 79 Next >

3 S&P 500 Stocks We Approach with Caution

October 10, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Intellectual Property Stocks

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

October 09, 2025

From Gilead Sciences, Inc.

Via Business Wire

Breaking Down Gilead Sciences: 6 Analysts Share Their Views ↗

October 08, 2025

Via Benzinga

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗

October 08, 2025

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Via Investor's Business Daily

Lupin Gains On FDA Nod For HIV Drug; Technicals Suggest Potential Upside Above ₹2,060 ↗

September 25, 2025

Via Stocktwits

Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors ↗

October 08, 2025

Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.

Via Chartmill

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

October 07, 2025

Via Benzinga

Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway ↗

October 06, 2025

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.

Via Stocktwits

Topics Intellectual Property

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036 ↗

October 06, 2025

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.

Via Benzinga

Topics Intellectual Property

Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO ↗

October 06, 2025

The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.

Via Investor's Business Daily

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump ↗

October 06, 2025

The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.

Via Investor's Business Daily

Topics Intellectual Property

Discover the top S&P500 movers in Monday's pre-market session. ↗

October 06, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Via Chartmill

2 Surefire Dividend Stocks to Buy for the Long Haul ↗

October 04, 2025

Both have crushed the market in 2025.

Via The Motley Fool

Topics Economy Government Intellectual Property

Is Gilead Sciences Inc Gaining or Losing Market Support? ↗

October 02, 2025

Via Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap ↗

October 02, 2025

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

Via Benzinga

Market Whales and Their Recent Bets on GILD Options ↗

October 02, 2025

Via Benzinga

2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off

October 01, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Topics Credit Cards

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears

September 29, 2025

As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a...

Via MarketMinute

Topics Bonds Economy Government

September 29, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

September 25, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Inc (NASDAQ:GILD) Shows Strong Technical Setup for Potential Breakout ↗

September 24, 2025

Gilead Sciences (GILD) shows strong technicals with a top rating of 9. It's forming a high-quality consolidation pattern, suggesting a potential breakout above $117.42.

Via Chartmill

If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

September 23, 2025

Via Benzinga

3 Profitable Stocks We’re Skeptical Of

September 23, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Cumberland First in Families to Host 2nd Annual Mister & Miss FIFNC Pageant

September 18, 2025

Via Get News

What Analysts Are Saying About Gilead Sciences Stock ↗

September 16, 2025

Via Benzinga

3 Reasons GILD is Risky and 1 Stock to Buy Instead

September 16, 2025

Gilead Sciences has been treading water for the past six months, holding steady at $112.78. The stock also fell short of the S&P 500’s 16.5% gain during that period.

Via StockStory

Topics Government Stocks

U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession

September 15, 2025

The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

These S&P500 stocks are gapping in today's session ↗

September 15, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends.

Via Chartmill

Biotech Sector May Flip to Market Leader by Year-End ↗

September 15, 2025

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

Via MarketBeat

Topics ETFs Economy Stocks

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.